-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Central point |vascular immune mother T-cell lymphoma (AITL) modern methods of treatment is still not ideal; a new prognostic score divided with different clinical outcomes of low, medium and high risk AITL subgroups
.
.
The center point of | the central point |vascularimmunelymphoma
Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL), with unique clinicopathological characteristics, strong aggressiveness, and poor prognosis
.
In a recent study published in the journal Blood , Ranjana et al .
conducted a subgroup analysis of 282 AITL patients who participated in the international prospective T cell project between 2006 and 2018
.
The primary and secondary endpoints are 5-year overall survival (OS) and progression-free survival (PFS), respectively
"Blood" 282 AITL
Overall OS and PFS
Overall OS and PFSThe median age of the tested patients was 64 years old, and 90% of the patients had advanced disease
.
81% of patients received anthracycline-based regimens, and 13% of patients received consolidated autologous stem cell transplantation (ASCT) when they achieved complete remission (CR1) for the first time
The estimated 5-year OS and PFS of
OS and PFS in patients with or without ASCT in complete remission
OS and PFS in patients with or without ASCT in complete remissionIn multivariate analysis, ≥60 years of age, ECOG performance status>2, elevated C-reactive protein and elevated β2 microglobulin were all associated with poor prognosis
.
A new prognostic score (AITL score) that combines the above factors divides the low, medium, and high risk subgroups, and the corresponding 5-year OS estimates are 63%, 54%, and 21% , respectively , which have a better prognosis index than the established prognosis index.
A new prognostic score (AITL score) divides the low, medium, and high risk subgroups, and the corresponding 5-year OS estimates are 63%, 54%, and 21%, respectively.
OS and PFS in patients with or without POD24
OS and PFS in patients with or without POD24Finally, POD24 is a powerful prognostic factor.
The 5-year OS of patients without POD24 is as high as 63%, while the 5-year OS of patients with POD24 is only 6% (p<0.
0001)
.
The 5-year OS of patients without POD24 is as high as 63%, while the 5-year OS of patients with POD24 is only 6%.
POD24 is a strong prognostic factor.
The 5-year OS of patients without POD24 OS is as high as 63%, while the 5-year OS of patients with POD24 is only 6%
All in all, the best treatment for AITL is still an unmet need, and we need to explore new treatment methods
.
The results of this study need to be further verified in a prospective cohort study
Original source:
Original source:Ranjana H.
Outcomes and prognostic factors in angioimmunoblastic T- cell lymphoma: final report from the international T-cell Project in this message
